Literature DB >> 11105655

Reward deficiency syndrome: genetic aspects of behavioral disorders.

D E Comings1, K Blum.   

Abstract

The dopaminergic and opioidergic reward pathways of the brain are critical for survival since they provide the pleasure drives for eating, love and reproduction; these are called 'natural rewards' and involve the release of dopamine in the nucleus accumbens and frontal lobes. However, the same release of dopamine and production of sensations of pleasure can be produced by 'unnatural rewards' such as alcohol, cocaine, methamphetamine, heroin, nicotine, marijuana, and other drugs, and by compulsive activities such as gambling, eating, and sex, and by risk taking behaviors. Since only a minority of individuals become addicted to these compounds or behaviors, it is reasonable to ask what factors distinguish those who do become addicted from those who do not. It has usually been assumed that these behaviors are entirely voluntary and that environmental factors play the major role; however, since all of these behaviors have a significant genetic component, the presence of one or more variant genes presumably act as risk factors for these behaviors. Since the primary neurotransmitter of the reward pathway is dopamine, genes for dopamine synthesis, degradation, receptors, and transporters are reasonable candidates. However, serotonin, norepinephrine, GABA, opioid, and cannabinoid neurons all modify dopamine metabolism and dopamine neurons. We have proposed that defects in various combinations of the genes for these neurotransmitters result in a Reward Deficiency Syndrome (RDS) and that such individuals are at risk for abuse of the unnatural rewards. Because of its importance, the gene for the [figure: see text] dopamine D2 receptor was a major candidate gene. Studies in the past decade have shown that in various subject groups the Taq I A1 allele of the DRD2 gene is associated with alcoholism, drug abuse, smoking, obesity, compulsive gambling, and several personality traits. A range of other dopamine, opioid, cannabinoid, norepinephrine, and related genes have since been added to the list. Like other behavioral disorders, these are polygenically inherited and each gene accounts for only a small per cent of the variance. Techniques such as the Multivariate Analysis of Associations, which simultaneously examine the contribution of multiple genes, hold promise for understanding the genetic make up of polygenic disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11105655     DOI: 10.1016/S0079-6123(00)26022-6

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  187 in total

1.  Momentary affect surrounding loss of control and overeating in obese adults with and without binge eating disorder.

Authors:  Andrea B Goldschmidt; Scott G Engel; Stephen A Wonderlich; Ross D Crosby; Carol B Peterson; Daniel Le Grange; Marian Tanofsky-Kraff; Li Cao; James E Mitchell
Journal:  Obesity (Silver Spring)       Date:  2011-09-22       Impact factor: 5.002

Review 2.  Neuropsychopharmacology and neurogenetic aspects of executive functioning: should reward gene polymorphisms constitute a diagnostic tool to identify individuals at risk for impaired judgment?

Authors:  Abdalla Bowirrat; Thomas J H Chen; Marlene Oscar-Berman; Margaret Madigan; Amanda Lh Chen; John A Bailey; Eric R Braverman; Mallory Kerner; John Giordano; Siobhan Morse; B William Downs; Roger L Waite; Frank Fornari; Zaher Armaly; Kenneth Blum
Journal:  Mol Neurobiol       Date:  2012-02-28       Impact factor: 5.590

3.  [Pathological gambling. Impulse control disorder, addiction or compulsion?].

Authors:  N Schoofs; A Heinz
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

4.  Personality and overweight in 6-12-year-old children.

Authors:  S E Hampson; M E Vollrath; P B Júlíusson
Journal:  Pediatr Obes       Date:  2015-02-27       Impact factor: 4.000

5.  Coupling Genetic Addiction Risk Score (GARS) and Pro Dopamine Regulation (KB220) to Combat Substance Use Disorder (SUD).

Authors:  Kenneth Blum; Margaret A Madigan; Lyle Fried; Eric R Braverman; John Giordano; Rajendra D Badgaiyan
Journal:  Glob J Addict Rehabil Med       Date:  2017-02-23

6.  Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.

Authors:  Doug Hyun Han; Sun Mi Kim; Jung Eun Choi; Kyung Joon Min; Perry F Renshaw
Journal:  J Psychopharmacol       Date:  2013-01-16       Impact factor: 4.153

7.  A variant in ANKK1 modulates acute subjective effects of cocaine: a preliminary study.

Authors:  C J Spellicy; M J Harding; S C Hamon; J J Mahoney; J A Reyes; T R Kosten; T F Newton; R De La Garza; D A Nielsen
Journal:  Genes Brain Behav       Date:  2014-03-17       Impact factor: 3.449

8.  Risk-taking and sensation-seeking propensity in postinstitutionalized early adolescents.

Authors:  Michelle M Loman; Anna E Johnson; Karina Quevedo; Theresa L Lafavor; Megan R Gunnar
Journal:  J Child Psychol Psychiatry       Date:  2014-02-19       Impact factor: 8.982

Review 9.  Genetic and environmental influences on psychiatric comorbidity: a systematic review.

Authors:  M Cerdá; A Sagdeo; J Johnson; S Galea
Journal:  J Affect Disord       Date:  2009-12-11       Impact factor: 4.839

Review 10.  Pain and analgesia: the value of salience circuits.

Authors:  David Borsook; Robert Edwards; Igor Elman; Lino Becerra; Jon Levine
Journal:  Prog Neurobiol       Date:  2013-03-07       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.